Therapeutic cancer vaccines aim to induce de-novo immune responses against cancer cells by promoting the activation and subsequent expansion of tumor-specific CD8+ or CD4+ T cells, which mediate anti-tumor immunity. This evidence concerns the gene CD8A and cancer.